We apply for the first competitive renewal of ROl A141420 'Second receptors for primate immunodeficiency viruses."""""""" Our overall goal is to gain additional knowledge of the roles played by coreceptors in mediating HIV-1 entry, with emphasis on understanding how inhibitors of this process act, where they bind, and how the virus can escape their actions.
In Specific Aim 1, we will characterize escape pathways for coreceptor-targeted inhibitors of H!V-1 entry in vitro. We will generate escape mutants of an R5 HIV-1 primary isolate, using primary cells as targets, under the selection pressure of small molecule inhibitors, specific MAbs and CC-chemokines. We will determine whether the escape mutant viruses still use CCR5 or have instead, or as well, evolved the ability to use other coreceptors such as CXCR4. We will determine which sequence changes in the env gene are responsible for conferring the resistant phenotype. If the resistant viruses still use CCR5, we will investigate how, by using specific point mutants of CCR5.
In Specific Aim 2, we will evaluate HIV-1 entry inhibitors using cells derived from the gut and from cord blood, in macrophages and in cells expressing different levels of CCR5 We will see whether the potency of CCR5 inhibitors is influenced by the level of CCR5 expression on the surface of CD4+ target cells, in vitro, using both primary cells and engineered cell lines. We will determine whether either parameter correlates with known CCR5 promoter genotypes, since this may influence cell surface CCR5 expression. We will study relevant target cells for HlV-1 replication in vivo, including cells isolated from gut associated lymphoid tissue. We will also study the mechanism of action of CCR5 inhibitors, using biosensor methodology.
Specific Aim 3 is to investigate the determinants of rapid progression in SIV-infected macaques and thereby identify the SIV coreceptor that is the counterpart of CXCR4 in HIV-1 -infected humans. We will use specific inhibitors targeted at CCR5 to block this pathway for SIV entry into macaque PBMC, and thereby identify donor macaques that exhibit CCR5-inhibitor insensitive SIV entry in vitro. We hypothesize that this is due to the use of a different SIV coreceptor that is expressed at sufficient levels in cells from only a subset of animals. We will determine whether there is any correlation between CCR5-inhibitor insensitive SIV entry in vitro, and rapid progression upon SIV infection in vivo, by performing retrospective analyses of the outcome of Sly infection. We will identify what coreceptor(s) mediate CCR5-inhibitor insensitive SIV entry in vitro.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI041420-07
Application #
6510731
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Young, Janet M
Project Start
1997-07-01
Project End
2006-05-31
Budget Start
2002-06-01
Budget End
2003-05-31
Support Year
7
Fiscal Year
2002
Total Cost
$423,750
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Pugach, Pavel; Ozorowski, Gabriel; Cupo, Albert et al. (2015) A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89:3380-95
Guttman, Miklos; Garcia, Natalie K; Cupo, Albert et al. (2014) CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22:974-84
Berro, Reem; Yasmeen, Anila; Abrol, Ravinder et al. (2013) Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. J Virol 87:6569-81
Klasse, P J (2013) Structural biology. A new bundle of prospects for blocking HIV-1 entry. Science 341:1347-8
Parker, Zahra F; Iyer, Shilpa S; Wilen, Craig B et al. (2013) Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol 87:2401-11
Berro, Reem; Klasse, Per Johan; Jakobsen, Martin R et al. (2012) V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology 427:158-65
Klasse, Per Johan (2012) The molecular basis of HIV entry. Cell Microbiol 14:1183-92
Anastassopoulou, Cleo G; Ketas, Thomas J; Sanders, Rogier W et al. (2012) Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance. Virology 428:86-97
Henrich, Timothy J; Lewine, Nicolas R P; Lee, Sun-Hee et al. (2012) Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists. Antimicrob Agents Chemother 56:1931-5
Berro, Reem; Klasse, Per Johan; Lascano, Danny et al. (2011) Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J Virol 85:8227-40

Showing the most recent 10 out of 45 publications